A multi-institutional, prospective, observational study of a combination of atezolizumab and chemotherapy for patients with large cell neuroendocrine carcinoma (LCNEC) of the lung (NEJ044)

A multi-institutional, prospective, observational study of a combination of atezolizumab and chemotherapy for patients with large cell neuroendocrine carcinoma (LCNEC) of the lung (NEJ044) - Atezolizumab and chemotherapy for LCNEC (NEJ044)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040876

Enrollment

100

Registered

2020-06-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large cell neuroendocrine carcinoma (LCNEC) of the lung

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically-confirmed, advanced, metastatic, or postoperative recurrent, large cell neuroendocrine carcinoma (LCNEC) of the lung. 2. No prior systemic treatment for advanced/metastatic LCNEC. Subjects who received prior pre-operative, post-operative, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months since the last treatment. 3. Subject who is going to receive following combination therapy: (i) atezolizumab with carboplatin, paclitaxel and bevacizumab, (ii) atezoizumab with carboplatin and nab-paclitaxel, (iii) atezolizumab with carboplatin and etoposide. 4. 20 years of age or older. 5. Signed Informed Consent Form

Exclusion criteria

Exclusion criteria: 1. Subjects who could not give their consent. 2. Subjects with illnesses or conditions that interfere with their capacity to understand, follow and/or comply with study procedures.

Design outcomes

Primary

Measure	Time frame
1-year survival rate	—

Countries

Japan

Contacts

Public ContactTetsuhiko Asao

Juntendo University Graduate School of Medicine Department of Respiratory Medicine

tasao@juntendo.ac.jp03-3813-3111

Outcome results